183 related articles for article (PubMed ID: 36482411)
21. Effects of the Aurora kinases pan-inhibitor SNS-314 mesylate on anaplastic thyroid cancer derived cell lines.
Baldini E; Sorrenti S; D'Armiento E; Guaitoli E; Morrone S; D'Andrea V; Gnessi L; Moretti C; Antonelli A; Catania A; De Antoni E; Ulisse S
Clin Ter; 2012; 163(5):e307-13. PubMed ID: 23099978
[TBL] [Abstract][Full Text] [Related]
22. Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition.
Schweppe RE; Kerege AA; Sharma V; Poczobutt JM; Gutierrez-Hartmann A; Grzywa RL; Haugen BR
Thyroid; 2009 Aug; 19(8):825-35. PubMed ID: 19500021
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases.
Sini P; Gürtler U; Zahn SK; Baumann C; Rudolph D; Baumgartinger R; Strauss E; Haslinger C; Tontsch-Grunt U; Waizenegger IC; Solca F; Bader G; Zoephel A; Treu M; Reiser U; Garin-Chesa P; Boehmelt G; Kraut N; Quant J; Adolf GR
Mol Cancer Ther; 2016 Oct; 15(10):2388-2398. PubMed ID: 27496137
[TBL] [Abstract][Full Text] [Related]
24. Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines.
Arlot-Bonnemains Y; Baldini E; Martin B; Delcros JG; Toller M; Curcio F; Ambesi-Impiombato FS; D'Armiento M; Ulisse S
Endocr Relat Cancer; 2008 Jun; 15(2):559-68. PubMed ID: 18430894
[TBL] [Abstract][Full Text] [Related]
25. A Novel Tyrosine Kinase Inhibitor Can Augment Radioactive Iodine Uptake Through Endogenous Sodium/Iodide Symporter Expression in Anaplastic Thyroid Cancer.
Oh JM; Baek SH; Gangadaran P; Hong CM; Rajendran RL; Lee HW; Zhu L; Gopal A; Kalimuthu S; Jeong SY; Lee SW; Lee J; Ahn BC
Thyroid; 2020 Apr; 30(4):501-518. PubMed ID: 31928162
[No Abstract] [Full Text] [Related]
26. Histone deacetylase inhibition affects sodium iodide symporter expression and induces 131I cytotoxicity in anaplastic thyroid cancer cells.
Pugliese M; Fortunati N; Germano A; Asioli S; Marano F; Palestini N; Frairia R; Boccuzzi G; Catalano MG
Thyroid; 2013 Jul; 23(7):838-46. PubMed ID: 23531031
[TBL] [Abstract][Full Text] [Related]
27. Wild-Type P53 Induces Sodium/Iodide Symporter Expression Allowing Radioiodide Therapy in Anaplastic Thyroid Cancer.
Liu L; Li D; Chen Z; Yang J; Ma Y; Cai H; Shan C; Lv Z; Zhang X
Cell Physiol Biochem; 2017; 43(3):905-914. PubMed ID: 28957796
[TBL] [Abstract][Full Text] [Related]
28. Digitalislike Compounds Restore hNIS Expression and Iodide Uptake Capacity in Anaplastic Thyroid Cancer.
Tesselaar MH; Crezee T; Schuurmans I; Gerrits D; Nagarajah J; Boerman OC; van Engen-van Grunsven I; Smit JWA; Netea-Maier RT; Plantinga TS
J Nucl Med; 2018 May; 59(5):780-786. PubMed ID: 29242405
[TBL] [Abstract][Full Text] [Related]
29. Abemaciclib (CDK4/6 Inhibitor) Blockade Induces Cytotoxicity in Human Anaplastic Thyroid Carcinoma Cells.
Seyed Abutorabi E; Irani S; Yaghmaie M; Ghaffari SH
Rep Biochem Mol Biol; 2020 Jan; 8(4):438-445. PubMed ID: 32582803
[TBL] [Abstract][Full Text] [Related]
30. A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer.
Lin SF; Lin JD; Hsueh C; Chou TC; Wong RJ
PLoS One; 2017; 12(2):e0172315. PubMed ID: 28207834
[TBL] [Abstract][Full Text] [Related]
31. Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma.
Nappi TC; Salerno P; Zitzelsberger H; Carlomagno F; Salvatore G; Santoro M
Cancer Res; 2009 Mar; 69(5):1916-23. PubMed ID: 19223553
[TBL] [Abstract][Full Text] [Related]
32. Relation of
Huang D; Huang Y; Huang Z; Weng J; Zhang S; Gu W
Cancer Cell Int; 2019; 19():166. PubMed ID: 31244554
[TBL] [Abstract][Full Text] [Related]
33. Switching from MAPK-dependent to MAPK-independent repression of the sodium-iodide symporter in 2D and 3D cultured normal thyroid cells.
Ingeson-Carlsson C; Nilsson M
Mol Cell Endocrinol; 2013 Dec; 381(1-2):241-54. PubMed ID: 23969277
[TBL] [Abstract][Full Text] [Related]
34. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.
McFadden DG; Vernon A; Santiago PM; Martinez-McFaline R; Bhutkar A; Crowley DM; McMahon M; Sadow PM; Jacks T
Proc Natl Acad Sci U S A; 2014 Apr; 111(16):E1600-9. PubMed ID: 24711431
[TBL] [Abstract][Full Text] [Related]
35. Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines.
Marampon F; Gravina GL; Popov VM; Scarsella L; Festuccia C; La Verghetta ME; Parente S; Cerasani M; Bruera G; Ficorella C; Ricevuto E; Tombolini V; Di Cesare E; Zani BM
Int J Oncol; 2014 Jan; 44(1):285-94. PubMed ID: 24189697
[TBL] [Abstract][Full Text] [Related]
36. In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines.
Zito G; Richiusa P; Bommarito A; Carissimi E; Russo L; Coppola A; Zerilli M; Rodolico V; Criscimanna A; Amato M; Pizzolanti G; Galluzzo A; Giordano C
PLoS One; 2008; 3(10):e3544. PubMed ID: 18958156
[TBL] [Abstract][Full Text] [Related]
37. Roles of reactive oxygen species, mitochondrial membrane potential, and p53 in evodiamine-induced apoptosis and G2/M arrest of human anaplastic thyroid carcinoma cells.
Chien CC; Wu MS; Chou SW; Jargalsaikhan G; Chen YC
Chin Med; 2021 Dec; 16(1):134. PubMed ID: 34886886
[TBL] [Abstract][Full Text] [Related]
38. Hesperetin activates the Notch1 signaling cascade, causes apoptosis, and induces cellular differentiation in anaplastic thyroid cancer.
Patel PN; Yu XM; Jaskula-Sztul R; Chen H
Ann Surg Oncol; 2014 Dec; 21 Suppl 4(0 4):S497-504. PubMed ID: 24419754
[TBL] [Abstract][Full Text] [Related]
39. Combined inhibition of cellular pathways as a future therapeutic option in fatal anaplastic thyroid cancer.
Wunderlich A; Roth S; Ramaswamy A; Greene BH; Brendel C; Hinterseher U; Bartsch DK; Hoffmann S
Endocrine; 2012 Dec; 42(3):637-46. PubMed ID: 22477151
[TBL] [Abstract][Full Text] [Related]
40. Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma.
Milošević Z; Banković J; Dinić J; Tsimplouli C; Sereti E; Dragoj M; Paunović V; Milovanović Z; Stepanović M; Tanić N; Dimas K; Pešić M
Cell Oncol (Dordr); 2018 Aug; 41(4):409-426. PubMed ID: 29790111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
